KPD Consolidation After Stem Cell Transplant for Newly Diagnosed Myeloma

This trial tests a stem cell transplant followed by two targeted therapies — a BCMA CAR-T and a GPRC5D/CD3 bispecific antibody — to treat newly diagnosed multiple myeloma that has ultra-high-risk features. The goal is to see if this combination can better control the disease.

This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.

This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.

This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.

This trial tests whether using belantamab mafodotin plus lenalidomide as long-term maintenance after an autologous stem cell transplant can keep multiple myeloma under control, guided by minimal residual disease (MRD). MRD is a very small amount of disease that may remain after transplant, and the study helps see if treating those patients better improves outcomes.

This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.